Kivelna 50 SR Tablet contains Desvenlafaxine 50mg, a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD) in adults. Desvenlafaxine functions by increasing the levels of neurotransmitters serotonin and norepinephrine in the central nervous system, thereby helping to restore the balance of these chemicals and improve mood, energy, and overall mental health. The sustained-release formulation ensures a gradual release of the active ingredient, promoting consistent therapeutic effects and improving patient compliance by allowing once-daily dosing. Kivelna 50 SR is prescribed to alleviate symptoms such as persistent sadness, loss of interest in daily activities, fatigue, and impaired concentration associated with depression. It may also be beneficial in managing anxiety disorders and certain chronic pain conditions, as determined by a healthcare professional. Common side effects include nausea, dizziness, dry mouth, and insomnia, which are generally transient and mild. Patients should be monitored for any signs of increased suicidal thoughts, especially during the initial treatment phase or dosage adjustments. Kivelna 50 SR should be used under medical supervision, with caution advised in individuals with a history of bipolar disorder, seizures, or hypertension. Abrupt discontinuation should be avoided to prevent withdrawal symptoms.